semaglutide will launch before 2025. These expected launches have the potential to expand the market for prescription antiobesity drugs. Pharma is currently testing anti-obesity drugs – the plan disincentives that . See inserted chart. Surbhi Gupta, 6-27-17. (Gupta: M. Pharm., Business Insights Analyst. “Emerging interest of Big Pharma in Obesity:Will the Market for Prescription Antiobesity Drugs see new light?” DRG. Accessed 8-2-17. JSD.) Is the molecule Major currently Molecule in Phase of Mechanism of pharmaceutical under pipeline development action Company development for type 2 diabetes? Glucagon-like Semaglutide Phase II peptide 1 (GLP-1) Yes receptor agonist Triple agonist of GLP-1, gastric Tri-agonist Phase I inhibitory peptide No 1706/NN9423 (GIP) and glucagon (GCG) receptors AM833/NN9838 Phase I Amylin analogue No Novo Nordisk G530S/NN9030 Phase I Glucagon analogue No FGF21 Fibroblast growth Phase I No Obesity/NN9499 factor 21 analogue Dual agonist of GG-co-agonist Phase I GLP-1 and GCG No 1177/NN9277 receptors Peptide YY PYY 1562/NN9747 Phase I Yes hormone analogue HM12525A/ Dual agonist of Johnson & Phase I GLP-1 and GCG Yes JNJ-64565111 Johnson receptors Sodium transport 1 Novartis LIK066 Phase II and 2 inhibitor Yes (SGLT-1/2 inhibitor)
semaglutide will launch before 2025. These expected launches have the potential to expand the market for prescription antiobesity drugs. Pharma is currently testing anti-obesity drugs – the plan disincentives that . See inserted chart. Surbhi Gupta, 6-27-17. (Gupta: M. Pharm., Business Insights Analyst. “Emerging interest of Big Pharma in Obesity:Will the Market for Prescription Antiobesity Drugs see new light?” DRG. Accessed 8-2-17. JSD.) Major pharmaceutical Company Molecule in pipeline Phase of development Mechanism of action Is the molecule currently under development for type 2 diabetes? Novo Nordisk Semaglutide Phase II Glucagon-like peptide 1 (GLP-1) receptor agonist Yes Tri-agonist 1706/NN9423 Phase I Triple agonist of GLP-1, gastric inhibitory peptide (GIP) and glucagon (GCG) receptors No AM833/NN9838 Phase I Amylin analogue No G530S/NN9030 Phase I Glucagon analogue No FGF21 Obesity/NN9499 Phase I Fibroblast growth factor 21 analogue No GG-co-agonist 1177/NN9277 Phase I Dual agonist of GLP-1 and GCG receptors No PYY 1562/NN9747 Phase I Peptide YY hormone analogue Yes Johnson & Johnson HM12525A/ JNJ-64565111 Phase I Dual agonist of GLP-1 and GCG receptors Yes Novartis LIK066 Phase II Sodium transport 1 and 2 inhibitor (SGLT-1/2 inhibitor) Yes